Tunghai University

Genmont Biotech Inc.

Ying-Chun Lai

Ming-Shiou Jan

Wan-Hua Tsai

Wen-Ling Yeh

Chang-Chi Hsieh

I-ling Hsu

Yen-Wan Hsiao

Li-Jin Hsu

Chuan-Kai Chou

Wee-wei Chieng

Shan-ju Hsu

Ai Shih

A probiotic composition for improving an effect of a chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is disclosed in the present disclosure. The probiotic composition comprises an effective amount ofGMNL-133, an effective amount ofGMNL-89, and a pharmaceutically acceptable carrier, wherein theGMNL-133 was deposited in the China Center for Type Culture Collection on Sep. 26, 2011 under an accession number CCTCC NO. M 2011331, and theGMNL-89 was deposited in the China Center for Type Culture Collection on Nov. 19, 2007 under an accession number CCTCC NO. M 207154. A method for improving the effect of the chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is further disclosed in the present disclosure.

Method for improving an effect of chemotherapeutic drug of gemcitabine on inhibiting pancreatic cancer and improving side effect of chemotherapeutic drug of Gemcitabine

This present invention relates to a screening method for rapidly identifying the hybridomas upon cell size and the expression of an exogenous label such as fluorescence labeling. This method of this present invention can largely shortens the time cost for antibody development by saving the time period with comparison of traditional methods using cell culture with media such as HAT medium.

Screening method for rapid identification of hybridomas

Growing community of inventors

Taichung, Taiwan

Ying-Chun Lai